Prognostic factors in pediatric high-grade astrocytoma: The importance of accurate pathologic diagnosis

Russell K. Hales, Ori Shokek, Peter C. Burger, Nina P. Paynter, Kaisorn L. Chaichana, Alfredo Quinones-Hinojosa, George I. Jallo, Kenneth J. Cohen, Danny Y. Song, Benjamin S. Carson, Moody D. Wharam

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To characterize a population of pediatric high-grade astrocytoma (HGA) patients by confirming the proportion with a correct diagnosis, and determine prognostic factors for survival in a subset diagnosed with uniform pathologic criteria. Sixty-three children diagnosed with HGA were treated at the Johns Hopkins Hospital between 1977 and 2004. A single neuropathologist (P.C.B.) reviewed all available histologic samples (n = 48). Log-rank analysis was used to compare survival by patient, tumor, and treatment factors. Median follow-up was 16 months for all patients and 155 months (minimum 54 months) for surviving patients. Median survival for all patients (n = 63) was 14 months with 10 long-term survivors (survival >48 months). At initial diagnosis, 27 patients were grade III (43%) and 36 grade IV (57%). Forty-eight patients had pathology slides available for review, including seven of ten long-term surviving patients. Four patients had non-HGA pathology, all of whom were long term survivors. The remaining 44 patients with confirmed HGG had a median survival of 14 months and prognostic analysis was confined to these patients. On multivariate analysis, five factors were associated with inferior survival: performance status (Lansky) <80% (13 vs. 15 months), bilaterality (13 vs. 19 months), parietal lobe location (13 vs. 16 months), resection less than gross total (13 vs. 22 months), and radiotherapy dose <50 Gy (9 vs. 16 months). Among patients with more than one of the five adverse factors (n = 27), median survival and proportion of long-term survivors were 12.9 months and 0%, compared with 41.4 months and 18% for patients with 0-1 adverse factors (n = 17). In an historical cohort of children with HGA, the potential for long term survival was confined to the subset with less than two of the following adverse prognostic factors: low performance status, bilaterality, parietal lobe site, less than gross total resection, and radiotherapy dose <50 Gy. Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
JournalJournal of Neuro-Oncology
Volume99
Issue number1
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Astrocytoma
Pediatrics
Survival
Survivors
Parietal Lobe
Radiotherapy
Pathology
Polychlorinated Biphenyls
Diagnostic Errors
Multivariate Analysis

Keywords

  • Anaplastic
  • Glioblastoma
  • Glioma
  • Misdiagnosis
  • Pediatrics
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)

Cite this

Prognostic factors in pediatric high-grade astrocytoma : The importance of accurate pathologic diagnosis. / Hales, Russell K.; Shokek, Ori; Burger, Peter C.; Paynter, Nina P.; Chaichana, Kaisorn L.; Quinones-Hinojosa, Alfredo; Jallo, George I.; Cohen, Kenneth J.; Song, Danny Y.; Carson, Benjamin S.; Wharam, Moody D.

In: Journal of Neuro-Oncology, Vol. 99, No. 1, 08.2010, p. 65-71.

Research output: Contribution to journalArticle

Hales, RK, Shokek, O, Burger, PC, Paynter, NP, Chaichana, KL, Quinones-Hinojosa, A, Jallo, GI, Cohen, KJ, Song, DY, Carson, BS & Wharam, MD 2010, 'Prognostic factors in pediatric high-grade astrocytoma: The importance of accurate pathologic diagnosis', Journal of Neuro-Oncology, vol. 99, no. 1, pp. 65-71. https://doi.org/10.1007/s11060-009-0102-3
Hales, Russell K. ; Shokek, Ori ; Burger, Peter C. ; Paynter, Nina P. ; Chaichana, Kaisorn L. ; Quinones-Hinojosa, Alfredo ; Jallo, George I. ; Cohen, Kenneth J. ; Song, Danny Y. ; Carson, Benjamin S. ; Wharam, Moody D. / Prognostic factors in pediatric high-grade astrocytoma : The importance of accurate pathologic diagnosis. In: Journal of Neuro-Oncology. 2010 ; Vol. 99, No. 1. pp. 65-71.
@article{f0aa68e9b2294e209176f8d0e98d6297,
title = "Prognostic factors in pediatric high-grade astrocytoma: The importance of accurate pathologic diagnosis",
abstract = "To characterize a population of pediatric high-grade astrocytoma (HGA) patients by confirming the proportion with a correct diagnosis, and determine prognostic factors for survival in a subset diagnosed with uniform pathologic criteria. Sixty-three children diagnosed with HGA were treated at the Johns Hopkins Hospital between 1977 and 2004. A single neuropathologist (P.C.B.) reviewed all available histologic samples (n = 48). Log-rank analysis was used to compare survival by patient, tumor, and treatment factors. Median follow-up was 16 months for all patients and 155 months (minimum 54 months) for surviving patients. Median survival for all patients (n = 63) was 14 months with 10 long-term survivors (survival >48 months). At initial diagnosis, 27 patients were grade III (43{\%}) and 36 grade IV (57{\%}). Forty-eight patients had pathology slides available for review, including seven of ten long-term surviving patients. Four patients had non-HGA pathology, all of whom were long term survivors. The remaining 44 patients with confirmed HGG had a median survival of 14 months and prognostic analysis was confined to these patients. On multivariate analysis, five factors were associated with inferior survival: performance status (Lansky) <80{\%} (13 vs. 15 months), bilaterality (13 vs. 19 months), parietal lobe location (13 vs. 16 months), resection less than gross total (13 vs. 22 months), and radiotherapy dose <50 Gy (9 vs. 16 months). Among patients with more than one of the five adverse factors (n = 27), median survival and proportion of long-term survivors were 12.9 months and 0{\%}, compared with 41.4 months and 18{\%} for patients with 0-1 adverse factors (n = 17). In an historical cohort of children with HGA, the potential for long term survival was confined to the subset with less than two of the following adverse prognostic factors: low performance status, bilaterality, parietal lobe site, less than gross total resection, and radiotherapy dose <50 Gy. Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma.",
keywords = "Anaplastic, Glioblastoma, Glioma, Misdiagnosis, Pediatrics, Prognosis, Survival",
author = "Hales, {Russell K.} and Ori Shokek and Burger, {Peter C.} and Paynter, {Nina P.} and Chaichana, {Kaisorn L.} and Alfredo Quinones-Hinojosa and Jallo, {George I.} and Cohen, {Kenneth J.} and Song, {Danny Y.} and Carson, {Benjamin S.} and Wharam, {Moody D.}",
year = "2010",
month = "8",
doi = "10.1007/s11060-009-0102-3",
language = "English (US)",
volume = "99",
pages = "65--71",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Prognostic factors in pediatric high-grade astrocytoma

T2 - The importance of accurate pathologic diagnosis

AU - Hales, Russell K.

AU - Shokek, Ori

AU - Burger, Peter C.

AU - Paynter, Nina P.

AU - Chaichana, Kaisorn L.

AU - Quinones-Hinojosa, Alfredo

AU - Jallo, George I.

AU - Cohen, Kenneth J.

AU - Song, Danny Y.

AU - Carson, Benjamin S.

AU - Wharam, Moody D.

PY - 2010/8

Y1 - 2010/8

N2 - To characterize a population of pediatric high-grade astrocytoma (HGA) patients by confirming the proportion with a correct diagnosis, and determine prognostic factors for survival in a subset diagnosed with uniform pathologic criteria. Sixty-three children diagnosed with HGA were treated at the Johns Hopkins Hospital between 1977 and 2004. A single neuropathologist (P.C.B.) reviewed all available histologic samples (n = 48). Log-rank analysis was used to compare survival by patient, tumor, and treatment factors. Median follow-up was 16 months for all patients and 155 months (minimum 54 months) for surviving patients. Median survival for all patients (n = 63) was 14 months with 10 long-term survivors (survival >48 months). At initial diagnosis, 27 patients were grade III (43%) and 36 grade IV (57%). Forty-eight patients had pathology slides available for review, including seven of ten long-term surviving patients. Four patients had non-HGA pathology, all of whom were long term survivors. The remaining 44 patients with confirmed HGG had a median survival of 14 months and prognostic analysis was confined to these patients. On multivariate analysis, five factors were associated with inferior survival: performance status (Lansky) <80% (13 vs. 15 months), bilaterality (13 vs. 19 months), parietal lobe location (13 vs. 16 months), resection less than gross total (13 vs. 22 months), and radiotherapy dose <50 Gy (9 vs. 16 months). Among patients with more than one of the five adverse factors (n = 27), median survival and proportion of long-term survivors were 12.9 months and 0%, compared with 41.4 months and 18% for patients with 0-1 adverse factors (n = 17). In an historical cohort of children with HGA, the potential for long term survival was confined to the subset with less than two of the following adverse prognostic factors: low performance status, bilaterality, parietal lobe site, less than gross total resection, and radiotherapy dose <50 Gy. Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma.

AB - To characterize a population of pediatric high-grade astrocytoma (HGA) patients by confirming the proportion with a correct diagnosis, and determine prognostic factors for survival in a subset diagnosed with uniform pathologic criteria. Sixty-three children diagnosed with HGA were treated at the Johns Hopkins Hospital between 1977 and 2004. A single neuropathologist (P.C.B.) reviewed all available histologic samples (n = 48). Log-rank analysis was used to compare survival by patient, tumor, and treatment factors. Median follow-up was 16 months for all patients and 155 months (minimum 54 months) for surviving patients. Median survival for all patients (n = 63) was 14 months with 10 long-term survivors (survival >48 months). At initial diagnosis, 27 patients were grade III (43%) and 36 grade IV (57%). Forty-eight patients had pathology slides available for review, including seven of ten long-term surviving patients. Four patients had non-HGA pathology, all of whom were long term survivors. The remaining 44 patients with confirmed HGG had a median survival of 14 months and prognostic analysis was confined to these patients. On multivariate analysis, five factors were associated with inferior survival: performance status (Lansky) <80% (13 vs. 15 months), bilaterality (13 vs. 19 months), parietal lobe location (13 vs. 16 months), resection less than gross total (13 vs. 22 months), and radiotherapy dose <50 Gy (9 vs. 16 months). Among patients with more than one of the five adverse factors (n = 27), median survival and proportion of long-term survivors were 12.9 months and 0%, compared with 41.4 months and 18% for patients with 0-1 adverse factors (n = 17). In an historical cohort of children with HGA, the potential for long term survival was confined to the subset with less than two of the following adverse prognostic factors: low performance status, bilaterality, parietal lobe site, less than gross total resection, and radiotherapy dose <50 Gy. Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma.

KW - Anaplastic

KW - Glioblastoma

KW - Glioma

KW - Misdiagnosis

KW - Pediatrics

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77954386605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954386605&partnerID=8YFLogxK

U2 - 10.1007/s11060-009-0102-3

DO - 10.1007/s11060-009-0102-3

M3 - Article

C2 - 20043190

AN - SCOPUS:77954386605

VL - 99

SP - 65

EP - 71

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -